Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus
Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.
You may also be interested in...
One of the recent recommendations for a Cancer Moonshot demonstration program is to implement genetic testing on a wider scale in family members of people with colon cancer-associated genetic mutations. But with greater visibility, how should the testing paradigm change?
Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.